Shipra Gandhi
@gandhi_shipra
Followers
673
Following
751
Statuses
755
Breast oncologist, translational researcher @RoswellPark Tweets are my own and not medical advice.
@RoswellPark
Joined June 2019
Spotlight Poster Discussion #1 "Racial Outcomes and Disparities" PD1-07 showing Black stage I-III breast cancer patients have worse outcomes, especially if did not attain pCR. Personalized treatment options to improve pCR desperately needed !!! @royaryam #SABCS22 @RoswellPark
2
2
28
RT @CharlesJiangMD: Fellow oncologists – check out my free visualization tool for adjuvant therapy risks & benefit discussion. It's built f…
0
3
0
RT @PTarantinoMD: Also highly recommended, the accompanying Impassion031 editorial by Natasha Hunter and Sarah Hurvitz, with a very nice re…
0
10
0
RT @SKabrajiMD: @KAhmedMD @OncBrothers @NeuroOnc @OncoAlert @FLBreastCancer @DrSGraff @PTarantinoMD @ErikaHamilton9 Ongoing clinical trial…
0
2
0
RT @DrJFriedberg: Timely Reporting of Patient-Reported Outcomes in Cancer Clinical Trials: PROs should be reported alongside surrogate outc…
0
6
0
RT @jitcancer: New #JITC review: Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for…
0
41
0
RT @btfoundation: Call for Abstracts: #SCHD25! Submit your groundbreaking research to be reviewed by our esteemed Abstract Committee: https…
0
3
0
RT @AbiSivaMD: Love this list of Oncology conferences for 2025! Exciting year ahead! #Oncology #CancerResearch #Oncology2025
0
1
0
RT @CancerTherAdvsr: Advances in early breast cancer from #SABCS24. With @AzkaAliMD and @Haddad_Sara7 of @ClevelandClinic, @MOliveira_MD of…
0
2
0
RT @malaksalharbi1: I am thrilled to share our recent collaboration with our breast pathology colleagues, exploring breast biomarkers evolu…
0
2
0
RT @MridulaGeorgeMD: Takeaways from ZEST 📌short lead time between det of ctDNA and recurrence ~5mos 📌Pts who had ➖ ctDNA conv to➕within 3m…
0
12
0
RT @dr_yakupergun: #SABCS24 & @NEJM IMSEMA trial: Axillary Surgery in Breast Cancer Omitting surgical axillary staging in patients with…
0
28
0
RT @DrHBurstein: Important presentation on anthracyclines and outcomes in TAILORx by OncotypeDX score. Anthracycline chemo benefit over TC…
0
55
0
RT @DrHBurstein: 2024 proving a big year for palbociclib in MBC - Inavolisib approval with palbo - PATINA @Otto_DFCI shows major benefit i…
0
13
0
RT @dr_yakupergun: What happened in breast cancer in 2024? A summary of important studies👇 #bcsm
0
121
0
RT @stolaney1: RS≥11: Anthracycline (T-AC vs TC) DRFI RS<31:97.0 vs 97.6% HR 1.24 RS≥31: 96.1% vs 91%, HR 0.32 (OS not sig) Premenop: 96…
0
22
0
RT @SuyogCancer: Approch to therapy for metastatic TNBC at the end of 2024. Money 💰 slide .@SABCSSanAntonio #SABCS24 @OncoAlert @OncBrothe…
0
50
0
RT @ErikaHamilton9: Great slide highlighting not only are TILs predictive of pCR...it also translates to being prognostic beyond pCR for go…
0
11
0
RT @shanestecklein: Proud to have our work on using a #TNBC #genomic score in combination with #TILs to predict response to neoadjuvant the…
0
3
0
RT @DrSGraff: 💡Making a critical point about how/why PATINA had such a high performance control arm, Dr Sara Hurvitz describes how the recr…
0
14
0
RT @malaksalharbi1: I am glad to present our study using SEER data(2010–2021), highlighting racial disparities and the impact of age at dia…
0
6
0